Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 11, 2026
TickeronGET DAILY SIGNALS
Hims & Hers Health (HIMS) Gains +12% Over 30 Days in Ongoing Rebound

Hims & Hers Health (HIMS) Gains +12% Over 30 Days in Ongoing Rebound

Key Takeaways

  • HIMS shares climbed roughly 12% over the past 30 days, rising from about $27.51 at the September 11, 2026 close to $30.92 at the October 9, 2026 close.
  • The advance reflects a rebound from a late-July selloff that pushed the stock to a low of $25.00 after an FTC lawsuit and a mixed second-quarter report.
  • Momentum was concentrated in a sharp +10% single-session gain on October 9 on elevated volume, alongside renewed analyst commentary and positioning ahead of third-quarter results.
  • Despite the rally, the stock remains roughly 10% below its mid-July level, underscoring persistent margin and regulatory concerns.

Understanding Hims & Hers Health (HIMS) Business Model

HIMS operates a San Francisco-based telehealth platform founded in 2017. It links consumers with licensed professionals and provides subscription access to treatments in areas such as sexual health, dermatology, mental health, hair loss, weight management, and newer offerings like testosterone therapy. Both prescription and over-the-counter products are sold under the Hims and Hers brands through a direct-to-consumer model focused on recurring revenue.

The company reported nearly 2.9 million subscribers in the second quarter of 2026 and has grown internationally via its Eucalyptus acquisition, which brought operations in Australia, the United Kingdom, and Germany. Investors track HIMS for its revenue expansion, entry into branded GLP-1 weight-loss drugs, and plans to integrate artificial intelligence into its care platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Performance Over the Past 30 Days and Quarter

From the September 11, 2026 close of $27.51, HIMS advanced to $30.92 by the October 9 close, for a gain of about 12%. Trading stayed mostly between $27 and $31 during the period until a decisive +10% move on October 9 pushed shares back above $30 on above-average volume.

The quarterly view is less straightforward. Shares traded in the mid-$30s in mid-July before dropping to a low of $25.00 on July 29. Recovery has been gradual into the upper-$20s and low-$30s, yet the stock is still down roughly 10% from its mid-July level. The recent 30-day gain has only partly offset the earlier decline. From what I see, this pattern highlights ongoing questions around margins and regulation.

Drivers of the 30-Day Advance

The move higher stemmed from a mix of recovery sentiment, analyst notes, and positioning ahead of earnings rather than one standout event. On October 7, 2026, the company named Jon Franklin as chief accounting officer, which some viewed as a step to bolster financial controls amid regulatory and billing attention.

The next day, Truist Securities kept a Hold rating and $32 target, pointing to proprietary credit-card data that showed third-quarter GLP-1 billing up about 22% quarter over quarter, even as September billing eased month over month. The note noted steady demand for branded weight-loss treatments alongside questions about momentum. Shares then rose 10% on October 9 on strong volume, which observers linked to pre-earnings repositioning.

Quarterly Performance Context

The broader quarterly drop followed two key developments in late July and early August. The FTC filed a lawsuit on July 29 alleging improper sharing of health data with third parties and misleading billing practices, which sent shares toward $25. On August 10, second-quarter results showed revenue up 38% year over year to $753.2 million, but gross margin fell to 64% from 76% a year earlier, and the company posted a wider loss after absorbing acquisition, restructuring, and legal costs.

The larger story has been the shift from compounded GLP-1 medications to branded, FDA-approved treatments, sped up by the settlement with Novo Nordisk (NVO). Management lifted full-year 2026 revenue guidance to $3.1 billion to $3.3 billion, yet lower margins and higher expenses have left investors weighing whether growth can lead to lasting profits. I checked the setup using Tickeron’s AI Trend Prediction Engine for additional context on the move.

What to Monitor Next for HIMS

The immediate focus is the third-quarter earnings report due in early November 2026. Attention will center on whether revenue growth stays near the upper end of guidance, if gross margins stabilize, and whether the branded GLP-1 transition improves unit economics.

Additional items include the FTC litigation outcome and any costs, progress with international expansion via Eucalyptus, returns on AI investments, and regulatory shifts around peptide and compounded treatments. Analyst views remain measured, with a consensus Hold rating and targets clustered around the low $30s, reflecting a cautious stance on profitability.

Using Tickeron AI Tools in My Research

When analyzing names like HIMS, I often turn to Tickeron’s AI Trading Bots for a rules-based perspective. These bots monitor thousands of tickers across different strategies and timeframes, letting me compare automated approaches without relying solely on discretionary calls. The platform helps surface data-driven options that align with my overall view of the setup.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HIMS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HIMS in downward trend: 10-day moving average moved below 50-day moving average on October 23, 2026

The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 66 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

HIMS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for HIMS entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in 240 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.719) is normal, around the industry mean (6.379). P/E Ratio (-41.935) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (183.387).

The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 62
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which is involved in real estate investment trusts

Industry PharmaceuticalsGeneric

Industry
N/A
Address
2269 Chestnut Street
Phone
+1 415 851-0195
Employees
2442
Web
https://www.forhims.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.